Researchers at the Ludwig-Maximilians-University, the German Center for Neurodegenerative Diseases (DZNE), and the Institute for Stroke and Dementia Research (ISD) in Munich, Germany, have identified a brain inflammation marker in patients at early asymptomatic stages of Alzheimer’s disease. This secreted marker molecule, which can be measured from cerebrospinal fluid taps, may provide clinicians with a rapidly detectable biomarker for the transition from preclinical Alzheimer’s disease to cognitive impairment and progression to full dementia. Such is the conclusion of a multi-center study on a large group of human patients, published online in EMBO Molecular Medicine.
from Dementia Big http://ift.tt/1QtSZTf
via Stopping Dementia
from WordPress http://ift.tt/1QuLv2k
via alcoholic dementia
http://ift.tt/1VU6qw2
No comments:
Post a Comment